Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1084 ± cetuximab in KRAS G12C-mutant advanced solid tumors (KANDLELIT-014)
jRCT2031250825Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of calderasib and cetuximab in Nonhematologic neoplasms (2 arms), sponsored by Merck & Co. Primary endpoints: Objective response rate, Adverse events and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
calderasibcetuximab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250825.